Drugs / Dialyzable Leukocyte Extract
Dialyzable Leukocyte Extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04379479 | May → Aug 2020 | COVID-19 | National Polytechnic Institute, Mexico | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dialyzable Leukocyte Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04379479 ↗ |
| Known as | DLE | “Dialyzable Leukocyte Extract (DLE) (Transferon oral®) is a dialyzed extract obtained from human leukocytes.” NCT04379479 ↗ |
| Known as | Transferon oral | “Dialyzable Leukocyte Extract (DLE) (Transferon oral®) is a dialyzed extract obtained from human leukocytes.” NCT04379479 ↗ |
| Modality | Peptide | “The peptide nature of DLE has been demonstrated using an aminogram method.” NCT04379479 ↗ |